Roche Licenses Sefaxersen from Ionis Pharmaceuticals
Roche has entered into a licensing agreement with Ionis Pharmaceuticals to acquire the rights to sefaxersen for the treatment of complement-mediated diseases.
Stocks · News reference
8-K filing — IONIS PHARMACEUTICALS INC (IONS)
Filed: 2026-10-23 AccNo: 0001140361-26-040631 Size: 186 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Roche announced positive interim phase III data from the IMAgINATION study showing that investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with primary IgA nephropathy. The antisense oligonucleotide inhibitor of complement factor B was well tolerated with no new safety signals and is designed as a once-monthly subcutaneous injection for self-administration.
BB Biotech Divests Remaining Stake in Ionis Pharmaceuticals
BB Biotech reported that it fully divested its remaining position in Ionis Pharmaceuticals during the third quarter of 2026.